| Name | Title | Contact Details |
|---|
Club Car Wash is a family-owned express car wash company based in Missouri. Founded in 2006 as Tiger Express Wash, it rebranded to Club Car Wash in 2019. The company has rapidly expanded to become one of the largest car wash chains in the Central United States, with over 213 locations and plans for 56 more by 2025. The company specializes in fast and convenient vehicle cleaning services, including exterior washes with advanced technology and various interior cleaning options. They offer membership and subscription plans for regular customers, as well as additional detailing services at select locations. Club Car Wash has grown through both organic development and acquisitions, enhancing its service offerings and geographic reach across multiple states. Their marketing focuses on quality, speed, and customer experience, catering to a diverse customer base that includes daily commuters and fleet operators.
American Guardian Warranty Services, Inc. (AGWS), part of the American Guardian Group of Companies, is one of the most trusted, service-focused vehicle service contract providers in the automotive, RV, powersports, marine, and commercial trucking markets. Headquartered just outside of Chicago, Illinois, AGWS is an innovative provider of administration services for Agents and Dealers offering vehicle protection products, limited warranties, and a variety of environmental and aftermarket products across the United States. Since its inception in 1998, the goals of AGWS are to offer superior claim processing, exceptional customer service, and unrivaled profitability options. Products are insured by "A" or "A-" (Excellent) rated carriers. AGWS is part of the American Guardian Group of Companies and enjoys an A+ rating with the Better Business Bureau.
Crossroads Automotive Group Inc. is a privately-held automotive dealership group based in Sanford, North Carolina, founded in 1996. The company specializes in new and used vehicle sales, service, and collision repair, operating multiple locations across North Carolina and Virginia. With a workforce of approximately 1,345 employees, Crossroads Automotive Group generates annual revenue of about $232 million. The company is committed to a customer-centric vehicle buying experience, guided by Christian principles. It emphasizes hiring skilled staff, maintaining large inventories, and providing compassionate service. Crossroads Automotive Group has expanded through acquisitions, including brands like Ford, Lincoln, INFINITI, Chrysler, Dodge, Jeep, and Ram. In addition to vehicle sales, the company offers automotive service, collision repair, maintenance, and financing options. It operates under various names, including Crossroads Ford and Crossroads Auto Group, and has established a strong presence in the automotive market.
Icreon is a leading customer experience transformation company providing organizations with digital strategy consulting, design, and engineering services at scale. Founded in 2000 and headquartered in New York with offices in London and New Delhi, Icreon specializes in serving Fortune 500 clients including industry leaders like Johnson Controls, Acrisure, Jets.com to the Major League Baseball Players Association. Fortune 500 companies, growing brands, and non-profits partner with Icreon to enable their next phase of growth through digital.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.